Drug Profile
Mesalazine/acetylcysteine
Alternative Names: Acetylcysteine/mesalamine; Acetylcysteine/mesalazine; ALTH12; Mesalamine/N-acetylcysteine; N-acetylcysteine/mesalamine; N-acetylcysteine/mesalazine; ZoenasaLatest Information Update: 03 Feb 2016
Price :
$50
*
At a glance
- Originator Altheus Therapeutics
- Class Aminosalicylic acids; Anti-inflammatories; Irritable bowel syndrome therapies; Reducing agents; Small molecules; Sulfur amino acids
- Mechanism of Action Antioxidants; Free radical inhibitors; Lipoxygenase-cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Crohn's disease; Gastrointestinal disorders; Ulcerative colitis; Ulcerative proctitis
Most Recent Events
- 23 Dec 2014 Phase-III clinical trials in Ulcerative colitis in USA (Rectal)
- 09 Jan 2014 Altheus Therapeutics completes enrolment in the phase II ZA-201 trial for Ulcerative colitis in the US (NCT01586533,
- 31 Dec 2013 Preclinical trials in Ulcerative colitis, Crohn's disease and Gastrointestinal disorders (in children) in USA (PO)